GLPBio

Apoptosis

Read More about this category

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

 

References:

1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.

2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.

3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.

4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.

5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Research Areas

Products Related to Apoptosis(3394)

  • GC72835 structure
    GC72835NSC260594
    CAS: 906718-66-9
    Purity: >96.00%

    NSC260594 induziert Apoptose.

  • GC72851 structure
    GC72851Belapectin
    CAS: 1980787-47-0
    Purity: >99.00%

    Belapectin (GR-MD-02) ist ein Galektin-3 (Gal-3)-Hemmer.

  • GC72858 structure
    GC72858Avenanthramide A
    CAS: 108605-70-5
    Purity: >99.00%

    Avenanthramide A ist ein Ptolexin, das in Hafer (Avena sativa L.) vorkommt.

  • GC72862 structure
    GC72862Erasin
    CAS: 2256056-21-8
    Purity: >95.00%

    Erasin ist eine starke Erlotinib-Resistenz, die STAT3-Inhibitor mit IC50s von 9,7 und 24 μM gegen STAT3 bzw. STAT1 antagonisiert.

  • GC72863 structure
    GC72863PZ703b TFA
    Purity: >98.00%

    PZ703b TFA ist ein Bcl-xl PROTAC Abbauprodukt, das Apoptose induziert und die Proliferation von Krebszellen für die Blasenkrebsforschung hemmt.

  • GC72864 structure
    GC72864PZ703b hydrochloride
    Purity: >99.00%

    PZ703b hydrochloride ist ein Bcl-xl PROTAC-Abbau, der Apoptose induziert und die Proliferation von Krebszellen hemmt.

  • GC72868 structure
    GC72868AZA197
    CAS: 1249398-09-1
    Purity: >98.00%

    AZA197 ist ein selektiver kleinmolekularer Inhibitor von Cdc42.

  • GC72875 structure
    GC72875Justicidin A
    CAS: 25001-57-4
    Purity: >99.00%

    Justicidin A ist ein Naturprodukt, das aus Justicia procumbens isoliert werden könnte.

  • GC72878 structure
    GC72878UCD38B hydrochloride
    CAS: 1115177-19-9
    Purity: >99.00%

    UCD38B hydrochloride ist ein zellpermeanter, kompetitiver enzymatischer uPA-Inhibitor mit einem IC50-Wert von 7 μM.

  • GC72892 structure
    GC72892Oblimersen sodium
    Purity: >98.00%

    Oblimersen sodium ist ein BCL-2-Inhibitor, der auf BCL-2 RNA abzielt.

  • GC72910 structure
    GC72910DD1
    CAS: 187585-11-1
    Purity: >99.00%

    DD1, ein Proteasom-Inhibitor, zielt auf die Bax-Aktivierung und den Abbau von P70S6K während der Apoptose der akuten myeloischen Leukämie (AML) ab.

  • GC72915 structure
    GC72915(R)-MRT199665
    Purity: >98.00%

    (R)-MRT199665 ist ein Isomer von MRT199665.

  • GC72924 structure
    GC72924PD173952
    CAS: 305820-75-1
    Purity: >99.00%

    PD173952 ist ein Tyrosinkinasen-Inhibitor mit IC50s von 0.3, 1.7 und 6.6 nM gegen Lyn, Abl und Csk.

  • GC72928 structure
    GC72928DB818
    CAS: 790241-43-9
    Purity: >98.00%

    DB818 ist ein starker Hemmer von Homeobox A9 (HOXA9).

  • GC72929 structure
    GC72929DB818 dihydrochloride

    DB818 dihydrochloride ist die Didrochloridsalzform von DB818.

  • GC72931 structure
    GC72931HTH-01-091 TFA
    Purity: >98.00%

    HTH-01-091 TFA ist ein potenter und selektiver mütterlicher embryonaler Leucin Zipper Kinase (MELK)-Hemmer mit einem IC50 von 10,5 nM.

  • GC72933 structure
    GC72933LQZ-7F
    CAS: 354543-09-2
    Purity: >97.00%

    LQZ-7F, ein Survivin-Dimerisierungshemmer, induziert spontane Apoptose und synergiert mit Docetaxel in Prostatakrebszellen.

  • GC72944 structure
    GC72944MMRi64
    CAS: 430458-66-5
    Purity: >98.00%

    MMRi64 stört Mdm2-MdmX-Interaktionen.

  • GC72971 structure
    GC72971INCB3619
    CAS: 791826-72-7
    Purity: >98.00%

    INCB3619 ist ein selektiver und oral aktiver ADAM-Inhibitor mit IC50 von 22 nM bzw. 14 nM für ADAM10 bzw. ADAM117.

  • GC72985 structure
    GC72985Z-LEVD-FMK
    CAS: 1135688-25-3
    Purity: >98.50%

    Z-LEVD-FMK ist ein zelldurchlässiger Caspase-4-Hemmer.

  • GC72991 structure
    GC72991(Rac)-Lisaftoclax
    CAS: 2651980-10-6
    Purity: >98.00%

    (Rac)-Lisaftoclax Rac-APG-2575 ist ein Bcl-2-Hemmer, der für die hämatologische Malignitätsforschung CN112898295A verwendet werden kann.

  • GC72994 structure
    GC72994RAPTA-C
    CAS: 372948-28-2
    Purity: >99.00%

    RAPTA-C (Ru(η6-p-cymen)Cl2(pta)) wirkt als Krebs- und Angiogenetikum.

  • GC73002 structure
    GC73002Ganglioside GD3 diammonium
    Purity: >98.00%

    Ganglioside GD3 diammonium ist ein saures Glykosphingolipid.

  • GC73016 structure
    GC73016AZD4877
    CAS: 758722-49-5
    Purity: >98.00%

    AZD4877 ist ein weiteres Isoster zu Ispinesib und auch ein Kinesinspindelprotein (Eg5)-Inhibitor mit IC50 von 2 nM.